The GLP-1 Paradox: A $100B Market That’s Barely Scratched the Surface

SAN MATEO, CA – July 02, 2026 – The story of GLP-1 agonists, the drug class behind brands like Ozempic, Wegovy, and Zepbound, is one of unprecedented velocity. With sales rocketing past $132 billion in 2025 and forecasts projecting a $200 billion market by 2030, these therapies represent one of the most explosive commercial successes in pharmaceutical history. Yet, beneath the surface of this gold rush, new research reveals a fractured and surprisingly nascent market, one defined as much by who is being left behind as by who is getting ahead.

New longitudinal data from health research firm Evidation offers a striking reality check. In a massive ongoing study of 165,000 individuals, the findings paint a picture not of a homogenous blockbuster revolution, but of a highly segmented landscape where access is uneven and the vast majority of the target population remains on the sidelines. For investors, providers, and patients, understanding this paradox is the key to identifying the true, long-term winners in an industry being reshaped in real time.

The Great Divide in Adoption

While GLP-1s dominate headlines, their adoption in the real world is far from universal. The Evidation data exposes stark fault lines across socioeconomic, gender, and age demographics, creating a clear portrait of a two-tiered system. The most telling disparity lies in income. As of May 2026, individuals in households earning over $150,000 were nearly twice as likely to have experience with GLP-1s (17%) as those in households earning less than $25,000 (9%). This gap points directly to the persistent headwinds of affordability and insurance coverage that define the patient journey.

A significant gender divide is also apparent. Women reported a 15% experience rate with the drugs, compared to just 9% for men, despite similar BMI profiles among non-users. This suggests different pathways to treatment, potentially influenced by prescribing patterns, marketing, or societal pressures. Age is another key differentiator, with adoption peaking among those aged 40-59, who reported experience rates between 17% and 19%.

“The GLP-1 market is growing quickly, but we're still in the early stages of understanding how people actually navigate treatment," noted Leslie Wilberforce, CEO of Evidation, in the company’s press release. “Our data show that experiences differ widely across populations, and factors like access, affordability, awareness, and personal preferences all matter.” These are not merely statistics; they are the identifying marks of systemic friction. For a therapy class with the potential to reshape public health by addressing obesity and its related cardiometabolic conditions, these disparities signal a fundamental challenge to achieving permanence and broad societal impact. A treatment that is only accessible to the wealthy and well-connected is not a solution, but a luxury.

An Ocean of Untapped Demand

For all the talk of a market nearing its saturation point, the most astonishing insight from Evidation’s research is just how much of the market remains untapped. The data reveals that among 119,000 people actively trying to lose weight, a staggering 85% have never tried a GLP-1. More broadly, 76% reported no lifetime use of any prescription weight-management medication. Many of these individuals are clinically eligible, with 39% having a BMI of 30 or higher, the clinical threshold for obesity.

This is the core of the GLP-1 paradox: a market generating over $100 billion annually is serving only a small fraction of its potential user base. This insight re-frames the narrative from one of a maturing duopoly—dominated by Novo Nordisk and Eli Lilly—to one of a land grab in its earliest phases. The growth from 9% to 12% in GLP-1 experience between May 2025 and May 2026, which accounted for nearly all growth in prescription weight-management, demonstrates the power of these drugs to capture new users. But the 85% of people still on the outside represents an opportunity that dwarfs the market’s current size.

Unlocking this demand is the central strategic challenge for the industry. Key catalysts are already in motion. The arrival of oral GLP-1s, like Novo Nordisk’s Rybelsus and Eli Lilly’s newly launched Foundayo (orforglipron), promises to lower the barrier to entry for patients hesitant about injections. Furthermore, the ongoing battle to expand insurance coverage, particularly securing Medicare access for obesity as a standalone indication, could bring millions of new patients into the fold. The industry's resilience will be tested by its ability to convert this vast, latent demand into sustained, equitable growth.

The Power of Real-World Data

This granular understanding of the market is made possible by a shift in how we gather health information. Evidation’s direct-from-participant model, which follows individuals over time, provides a crucial counterpoint to the sanitized environment of clinical trials. While trials prove a drug’s efficacy, longitudinal real-world data reveals its real-world effectiveness—or lack thereof. It captures the messy variables of daily life: the patient who stops taking a drug because of side effects, the one who can no longer afford the co-pay, or the one whose doctor never mentioned it as an option.

By tracking the journeys of 165,000 people, Evidation’s platform uncovers the “why” behind the numbers. “By following people over time, Evidation helps uncover why people start treatment, why they don't, and what supports better long-term outcomes,” Wilberforce explained. This is the kind of intelligence that separates fleeting success from permanent value. It allows companies to move beyond simply marketing a product to truly understanding and supporting the patient journey, a critical component of building lasting market leadership. For an industry built on innovation, the ability to harness and interpret this kind of data is rapidly becoming the most important competitive advantage.

Navigating the Headwinds of a Blockbuster Market

The path to capturing the full potential of the GLP-1 market is fraught with challenges. The current duopoly is engaged in a fierce battle for market share, leading to pricing pressures that saw Novo Nordisk brace for lower realized prices in 2026. Simultaneously, both Eli Lilly and Novo Nordisk are pouring tens of billions into manufacturing—a high-stakes bet that demand will not only continue but accelerate. Eli Lilly’s $27 billion U.S. manufacturing expansion underscores the scale of this gamble.

Furthermore, the specter of patent cliffs looms, with semaglutide facing loss of exclusivity in major international markets this year. This will inevitably introduce generic competition, further complicating pricing strategies and testing the brand loyalty these companies have built. The ultimate headwinds, however, may be political and perceptual. The stark socioeconomic divide revealed by Evidation’s data will only fuel the contentious debate over who should pay for these expensive therapies. The companies that demonstrate durable value—not just in weight loss but in reducing long-term healthcare costs—will be best positioned to win the support of payers and policymakers.

Ultimately, the resilience of the GLP-1 market and its key players will not be measured by quarterly sales figures alone. It will be determined by their ability to solve the paradox at the heart of their success: bridging the gap between a revolutionary therapy and the millions who need it but cannot access it. The winners in this new era will be those who can navigate these complex headwinds, turning a gilded-age product into a pillar of public health.